Please enable Javascript and disable ad blockers

Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN

DGAP-News: EVOTEC, INTEGRA HOLDINGS UND YISSUM STARTEN LAB555, UM FRÜHE WIRKSTOFFENTWICKLUNG ZU BESCHLEUNIGEN

0

DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg

DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT

DGAP-News: EVOTEC, INTEGRA HOLDINGS AND YISSUM ESTABLISH LAB555 TO FAST TRACK EARLY-STAGE DRUG DEVELOPMENT

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

DGAP-News: Erbsenproteine Peazazz and Peazac erhalten GRAS-Zulassung der U.S.-amerikanischen Lebensmittelbehörde FDA

DGAP-News: Erbsenproteine Peazazz and Peazac erhalten GRAS-Zulassung der U.S.-amerikanischen Lebensmittelbehörde FDA

DGAP-News: Erbsenproteine Peazazz and Peazac erhalten GRAS-Zulassung der U.S.-amerikanischen Lebensmittelbehörde FDA

0

DGAP-News: Peazazz and Peazac Pea Proteins FDA GRAS Notified

DGAP-News: Peazazz and Peazac Pea Proteins FDA GRAS Notified

DGAP-News: Peazazz and Peazac Pea Proteins FDA GRAS Notified

0

DGAP-News: Telefonkonferenz der MorphoSys AG am 30. Oktober 2019 zu den Ergebnissen des dritten Quartals 2019

DGAP-News: Telefonkonferenz der MorphoSys AG am 30. Oktober 2019 zu den Ergebnissen des dritten Quartals 2019

0

DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

DGAP-News: Invitation to MorphoSys Q3 2019 Conference Call on October 30, 2019

0

DGAP-Adhoc: CO.DON AG: co.don Aktiengesellschaft beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre

DGAP-Adhoc: CO.DON AG: co.don Aktiengesellschaft beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre

DGAP-Adhoc: CO.DON AG: co.don Aktiengesellschaft beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre

0

DGAP-Adhoc: CO.DON AG: co.don Aktiengesellschaft decides to increase share capital through rights issue with subscription rights of existing shareholders

DGAP-Adhoc: CO.DON AG: co.don Aktiengesellschaft decides to increase share capital through rights issue with subscription rights of existing shareholders

DGAP-Adhoc: CO.DON AG: co.don Aktiengesellschaft decides to increase share capital through rights issue with subscription rights of existing shareholders

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

DGAP-News: 4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

DGAP-News: 4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

DGAP-News: 4SC AG: Poster presentation at 1st International Symposium on Merkel Cell Carcinoma

0

DGAP-News: 4SC AG: Poster Präsentation auf dem 1st International Symposium on Merkel Cell Carcinoma

DGAP-News: 4SC AG: Poster Präsentation auf dem 1st International Symposium on Merkel Cell Carcinoma

DGAP-News: 4SC AG: Poster Präsentation auf dem 1st International Symposium on Merkel Cell Carcinoma

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

EQS-News: Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection

EQS-News: Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection

EQS-News: Great Bay Bio and Boji Medical have Reached Strategic Cooperation to Jointly Develop a Long-Acting Biological and Innovative Anti-Anemia Injection

0

DGAP-Adhoc: BB Biotech AG publishes its interim report

DGAP-Adhoc: BB Biotech AG publishes its interim report

DGAP-Adhoc: BB Biotech AG publishes its interim report

0

DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht

DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht

DGAP-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht

0

DGAP-News: BB BIOTECH AG: Political factors weigh on biotech equity markets

DGAP-News: BB BIOTECH AG: Political factors weigh on biotech equity markets

DGAP-News: BB BIOTECH AG: Political factors weigh on biotech equity markets

0

DGAP-News: BB BIOTECH AG: Politische Faktoren beeinflussen Biotechaktienmärkte

DGAP-News: BB BIOTECH AG: Politische Faktoren beeinflussen Biotechaktienmärkte

DGAP-News: BB BIOTECH AG: Politische Faktoren beeinflussen Biotechaktienmärkte

0

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

Form 8.3 - The Vanguard Group, Inc.: Allergan plc

0

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

Form 8.3 - The Vanguard Group, Inc.: AbbVie plc

0

DGAP-Adhoc: Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders

DGAP-Adhoc: Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders

DGAP-Adhoc: Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders

0

DGAP-Adhoc: Epigenomics AG beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre

DGAP-Adhoc: Epigenomics AG beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre

DGAP-Adhoc: Epigenomics AG beschließt Kapitalerhöhung mit Bezugsrecht der Aktionäre

0